Ownership Capital B.V. Sells 181,945 Shares of Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 17.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 849,649 shares of the life sciences company's stock after selling 181,945 shares during the quarter. Illumina comprises about 3.5% of Ownership Capital B.V.'s portfolio, making the stock its 15th biggest holding. Ownership Capital B.V. owned approximately 0.53% of Illumina worth $110,803,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Private Advisor Group LLC grew its holdings in shares of Illumina by 4.8% in the first quarter. Private Advisor Group LLC now owns 4,955 shares of the life sciences company's stock valued at $679,000 after purchasing an additional 226 shares during the period. Janney Montgomery Scott LLC grew its holdings in shares of Illumina by 41.5% in the first quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company's stock valued at $422,000 after purchasing an additional 900 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Illumina in the first quarter valued at about $645,000. Texas Permanent School Fund Corp lifted its position in Illumina by 0.3% in the first quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company's stock valued at $4,507,000 after buying an additional 114 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in Illumina by 426.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company's stock valued at $2,123,000 after buying an additional 12,521 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 2.6 %

Illumina stock traded down $4.06 during mid-day trading on Friday, hitting $151.09. The company's stock had a trading volume of 2,209,599 shares, compared to its average volume of 1,772,358. The firm's 50 day moving average is $138.09 and its 200 day moving average is $123.55. The company has a market cap of $23.96 billion, a PE ratio of -15.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 0.86. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm posted $0.33 EPS. The business's revenue was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Daiwa Capital Markets raised shares of Illumina from a "neutral" rating to a "buy" rating and upped their target price for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Canaccord Genuity Group upped their target price on shares of Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday, November 5th. Royal Bank of Canada increased their price target on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Argus raised shares of Illumina from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a report on Wednesday, August 28th. Finally, TD Cowen raised their target price on shares of Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $162.18.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.